TxCell appoints new CEO
This article was originally published in Scrip
French biotech company TxCell, which develops cell-based therapies for severe chronic inflammatory diseases, has appointed Dr François Meyer as chief executive officer. Dr Meyer has held senior positions at Ciba-Geigy Pharma, Sandoz Pharma, Gencell and Aventis Pharma, and until 2006 served as CEO of Centelion. Dr Meyer joins as TxCell – a spin-off of the French National Institute for Health and Medical Research (Inserm) – prepares to move two product candidates through clinical trials: Phase IIb trials for refractory Crohn's disease and Phase I/II trials for refractory rheumatoid arthritis respectively.